Aptamer Group Ltd publishes review in European Biopharmaceutical Review for Targeted Treatment
Published on 31/07/2018
The use of antibody-drug conjugates has become particularly prevalent in cancer therapy, although their development can be problematic in their execution. However, aptamers can be used as alternative affinity ligands to overcome these drawbacks.
The article from European Biopharmaceutical Review July 2018, pages 38-44. Samedan Ltd. can be accessed via the Aptamer Group Ltd website at http://bit.ly/EBRtargetedtreatment